Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Trinity Biotech (TRIB) Gross Profit (2016 - 2024)

Trinity Biotech's Gross Profit history spans 16 years, with the latest figure at $4.9 million for Q4 2024.

  • On a quarterly basis, Gross Profit rose 6.79% to $4.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $21.4 million, a 10.24% increase, with the full-year FY2025 number at $16.9 million, down 21.24% from a year prior.
  • Gross Profit hit $4.9 million in Q4 2024 for Trinity Biotech, down from $5.3 million in the prior quarter.
  • Over the last five years, Gross Profit for TRIB hit a ceiling of $16.8 million in Q3 2020 and a floor of $329000.0 in Q3 2022.
  • Historically, Gross Profit has averaged $7.2 million across 5 years, with a median of $5.7 million in 2022.
  • Biggest five-year swings in Gross Profit: plummeted 96.3% in 2022 and later soared 1200.91% in 2023.
  • Tracing TRIB's Gross Profit over 5 years: stood at $15.7 million in 2020, then tumbled by 53.77% to $7.2 million in 2021, then fell by 25.75% to $5.4 million in 2022, then decreased by 15.03% to $4.6 million in 2023, then increased by 6.79% to $4.9 million in 2024.
  • Business Quant data shows Gross Profit for TRIB at $4.9 million in Q4 2024, $5.3 million in Q3 2024, and $5.7 million in Q2 2024.